BIO-TECHNE Corp (TECH) stock
TECHNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3040% above fair value
$72.80−0.02 (-0.03%)
Close on Nov 11, 2026Market cap $11.43BP/E 66.8Yield 0.44%
Bio-Techne total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Bio-Techne's total debt was $200.00M at Sep 30, 2026. For fiscal 2026 it was $200.00M, down 42.2% from the year before. Over ten years it grew 8.1% a year on average. The highest annual figure on record is $505.16M in fiscal 2019.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $200.00M | -42.2% |
| FY2025 | Jun 30, 2025 | $346.00M | +8.5% |
| FY2024 | Jun 30, 2024 | $319.00M | -8.9% |
| FY2023 | Jun 30, 2023 | $350.00M | +36.8% |
| FY2022 | Jun 30, 2022 | $255.91M | -25.0% |
| FY2021 | Jun 30, 2021 | $341.33M | -4.3% |
| FY2020 | Jun 30, 2020 | $356.74M | -29.4% |
| FY2019 | Jun 30, 2019 | $505.16M | +49.0% |
| FY2018 | Jun 30, 2018 | $339.00M | -1.4% |
| FY2017 | Jun 30, 2017 | $343.77M | +275.7% |
| FY2016 | Jun 30, 2016 | $91.50M | +25.3% |
| FY2015 | Jun 30, 2015 | $73.00M | – |
| FY2014 | Jun 30, 2014 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | $200.00M | -33.3% |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $200.00M | -42.2% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $200.00M | -39.4% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $260.00M | -13.3% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $300.00M | 0.0% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $346.00M | +8.5% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $330.00M | -15.2% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $300.00M | -32.9% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $300.00M | -31.8% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $319.00M | -8.9% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $389.00M | +5.1% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $447.00M | +123.5% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $440.00M | +66.3% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $350.00M | +36.8% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $370.00M | +42.8% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $200.00M | -29.1% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $264.66M | -11.8% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $255.91M | -25.0% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $259.01M | +20.2% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $282.12M | +21.8% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $300.22M | -7.2% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $341.33M | -4.3% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $215.43M | -48.7% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $231.54M | -39.5% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $323.64M | -33.4% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $356.74M | -29.4% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $419.85M | -19.6% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $382.95M | -28.1% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $486.06M | -13.4% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $505.16M | +49.0% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $522.27M | +33.1% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $532.87M | +47.0% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $561.47M | +66.4% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $339.00M | -1.4% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $392.50M | +14.2% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $362.50M | +5.5% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $337.50M | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $343.77M | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $343.64M | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $343.66M | – |
See a number that looks wrong?